SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma
NCT04913480
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
37
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
Durvalumab
RADIATION:
Stereotactic body radiation therapy
Sponsor
The University of Hong Kong